JP2010529145A - 治療用ピラゾロナフチリジン誘導体 - Google Patents
治療用ピラゾロナフチリジン誘導体 Download PDFInfo
- Publication number
- JP2010529145A JP2010529145A JP2010511393A JP2010511393A JP2010529145A JP 2010529145 A JP2010529145 A JP 2010529145A JP 2010511393 A JP2010511393 A JP 2010511393A JP 2010511393 A JP2010511393 A JP 2010511393A JP 2010529145 A JP2010529145 A JP 2010529145A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- animal
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VMPCBEQFWHYVIV-UHFFFAOYSA-N C1=CC=N[C]2N[C]3C=NN=C3C=C21 Chemical class C1=CC=N[C]2N[C]3C=NN=C3C=C21 VMPCBEQFWHYVIV-UHFFFAOYSA-N 0.000 title description 5
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 143
- 238000000034 method Methods 0.000 claims abstract description 77
- 241001465754 Metazoa Species 0.000 claims abstract description 60
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 50
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 125000003118 aryl group Chemical group 0.000 claims description 92
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 55
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 125000001153 fluoro group Chemical group F* 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 27
- 230000015654 memory Effects 0.000 claims description 25
- -1 -NR a R b Chemical group 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 239000001301 oxygen Substances 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 208000010877 cognitive disease Diseases 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 230000003920 cognitive function Effects 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 208000020016 psychiatric disease Diseases 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 230000007787 long-term memory Effects 0.000 claims description 6
- 230000006403 short-term memory Effects 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 208000020685 sleep-wake disease Diseases 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 230000001668 ameliorated effect Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 14
- 108020003175 receptors Proteins 0.000 abstract description 14
- 229940049706 benzodiazepine Drugs 0.000 abstract description 6
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract description 5
- 230000027455 binding Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 230000003828 downregulation Effects 0.000 abstract description 3
- 102000004300 GABA-A Receptors Human genes 0.000 abstract description 2
- 108090000839 GABA-A Receptors Proteins 0.000 abstract description 2
- 102000027484 GABAA receptors Human genes 0.000 abstract 1
- 108091008681 GABAA receptors Proteins 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 56
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 40
- 238000005160 1H NMR spectroscopy Methods 0.000 description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 238000012549 training Methods 0.000 description 19
- 239000002904 solvent Substances 0.000 description 13
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 12
- 210000000287 oocyte Anatomy 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 239000012320 chlorinating reagent Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 4
- REUOCJLVDZPJEK-UHFFFAOYSA-N 3-chlorocinnoline Chemical compound C1=CC=C2N=NC(Cl)=CC2=C1 REUOCJLVDZPJEK-UHFFFAOYSA-N 0.000 description 4
- XZDABLUPZIKEAS-UHFFFAOYSA-N O=C1N(C=2C=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCNCC1 Chemical compound O=C1N(C=2C=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCNCC1 XZDABLUPZIKEAS-UHFFFAOYSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- CXUGAWWYKSOLEL-UHFFFAOYSA-N 2h-cinnolin-3-one Chemical compound C1=CC=C2N=NC(O)=CC2=C1 CXUGAWWYKSOLEL-UHFFFAOYSA-N 0.000 description 3
- HHRYDDRWORXLOW-UHFFFAOYSA-N C1CN(C)CCN1C1=CC=C(NC=C2C(N(C=3N=CC=CC=3)N=C22)=O)C2=N1 Chemical compound C1CN(C)CCN1C1=CC=C(NC=C2C(N(C=3N=CC=CC=3)N=C22)=O)C2=N1 HHRYDDRWORXLOW-UHFFFAOYSA-N 0.000 description 3
- 0 C=*c(cc1)ccc1N(CC1)CCN1c(nc1C2=NN3c4ccccc4)ccc1NC=C2C3=O Chemical compound C=*c(cc1)ccc1N(CC1)CCN1c(nc1C2=NN3c4ccccc4)ccc1NC=C2C3=O 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- UVZAIPRVSOBFOL-UHFFFAOYSA-N O=C1N(C=2C=CC=CC=2)N=C(C2=CC=N3)C1=CNC2=C3N1CCNCC1 Chemical compound O=C1N(C=2C=CC=CC=2)N=C(C2=CC=N3)C1=CNC2=C3N1CCNCC1 UVZAIPRVSOBFOL-UHFFFAOYSA-N 0.000 description 3
- PWUABIOOZPIRRX-UHFFFAOYSA-N O=C1N(C=2C=CC=CC=2)N=C(C2=CN=3)C1=CNC2=CC=3N1CCNCC1 Chemical compound O=C1N(C=2C=CC=CC=2)N=C(C2=CN=3)C1=CNC2=CC=3N1CCNCC1 PWUABIOOZPIRRX-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 3
- 229940067157 phenylhydrazine Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000003936 working memory Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 2
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- ZSJSVURISXUDBG-UHFFFAOYSA-N C1=CC(OC)=CC=C1N1C(=O)C2=CNC3=CC=C(N4CCN(C)CC4)N=C3C2=N1 Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CNC3=CC=C(N4CCN(C)CC4)N=C3C2=N1 ZSJSVURISXUDBG-UHFFFAOYSA-N 0.000 description 2
- OVKRIKXYUJPNJW-UHFFFAOYSA-N C1CC(O)CCN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 Chemical compound C1CC(O)CCN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 OVKRIKXYUJPNJW-UHFFFAOYSA-N 0.000 description 2
- KTGKKRPATFIFKO-UHFFFAOYSA-N C1CN(C)CCN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 Chemical compound C1CN(C)CCN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 KTGKKRPATFIFKO-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- FSGMTQGECCJGNK-UHFFFAOYSA-N O=C1N(C=2N=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCNCC1 Chemical compound O=C1N(C=2N=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCNCC1 FSGMTQGECCJGNK-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- GUJMUFSJFDQBJC-UHFFFAOYSA-N bis(trichloromethyl) carbonate;carbonyl dichloride Chemical compound ClC(Cl)=O.ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl GUJMUFSJFDQBJC-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- KPADFPAILITQBG-UHFFFAOYSA-N non-4-ene Chemical compound CCCCC=CCCC KPADFPAILITQBG-UHFFFAOYSA-N 0.000 description 2
- 229940078552 o-xylene Drugs 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- PVRSIFAEUCUJPK-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine Chemical compound COC1=CC=C(NN)C=C1 PVRSIFAEUCUJPK-UHFFFAOYSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical group NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- AVJKDKWRVSSJPK-UHFFFAOYSA-N 1-(4-fluorophenyl)piperazine Chemical compound C1=CC(F)=CC=C1N1CCNCC1 AVJKDKWRVSSJPK-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HNVIQLPOGUDBSU-UHFFFAOYSA-N 2,6-dimethylmorpholine Chemical compound CC1CNCC(C)O1 HNVIQLPOGUDBSU-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- YTHMOBMZVVFNBE-UHFFFAOYSA-N 6-fluoropyridin-3-amine Chemical compound NC1=CC=C(F)N=C1 YTHMOBMZVVFNBE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- BSFNZDWYVUYMKV-UHFFFAOYSA-N C12=NC(F)=CC=C2NC=C(C2=O)C1=NN2C1=CC=CC=C1 Chemical compound C12=NC(F)=CC=C2NC=C(C2=O)C1=NN2C1=CC=CC=C1 BSFNZDWYVUYMKV-UHFFFAOYSA-N 0.000 description 1
- BRORPADEUGVPTC-UHFFFAOYSA-N C12=NC(F)=CC=C2NC=C(C2=O)C1=NN2C1=CC=CC=N1 Chemical compound C12=NC(F)=CC=C2NC=C(C2=O)C1=NN2C1=CC=CC=N1 BRORPADEUGVPTC-UHFFFAOYSA-N 0.000 description 1
- QBIJGIIZBMBFAP-UHFFFAOYSA-N C1=2C=NC(Cl)=CC=2NC=C(C2=O)C1=NN2C1=CC=CC=C1 Chemical compound C1=2C=NC(Cl)=CC=2NC=C(C2=O)C1=NN2C1=CC=CC=C1 QBIJGIIZBMBFAP-UHFFFAOYSA-N 0.000 description 1
- ZLTDSOKDHYFFCO-UHFFFAOYSA-N C1=CC(F)=CC=C1N1CCN(C=2N=C3C=4C(C(N(C=5C=CC=CC=5)N=4)=O)=CNC3=CC=2)CC1 Chemical compound C1=CC(F)=CC=C1N1CCN(C=2N=C3C=4C(C(N(C=5C=CC=CC=5)N=4)=O)=CNC3=CC=2)CC1 ZLTDSOKDHYFFCO-UHFFFAOYSA-N 0.000 description 1
- QFDBHNPIDPQJTP-UHFFFAOYSA-N C1=CC(OC)=CC=C1N1C(=O)C2=CNC3=CC=C(F)N=C3C2=N1 Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=CNC3=CC=C(F)N=C3C2=N1 QFDBHNPIDPQJTP-UHFFFAOYSA-N 0.000 description 1
- FFVUAQYOIMKSGF-UHFFFAOYSA-N C1C(C)OC(C)CN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 Chemical compound C1C(C)OC(C)CN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 FFVUAQYOIMKSGF-UHFFFAOYSA-N 0.000 description 1
- YLIZTFTUFLAHDV-UHFFFAOYSA-N C1C(CO)CCCN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 Chemical compound C1C(CO)CCCN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 YLIZTFTUFLAHDV-UHFFFAOYSA-N 0.000 description 1
- IHKJMFJUGUWJDS-UHFFFAOYSA-N C1C(O)CCCN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 Chemical compound C1C(O)CCCN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 IHKJMFJUGUWJDS-UHFFFAOYSA-N 0.000 description 1
- LMOGWFDXSZTCNI-UHFFFAOYSA-N C1CN(C)CCCN1C1=CC=C(NC=C2C(N(C=3N=CC=CC=3)N=C22)=O)C2=N1 Chemical compound C1CN(C)CCCN1C1=CC=C(NC=C2C(N(C=3N=CC=CC=3)N=C22)=O)C2=N1 LMOGWFDXSZTCNI-UHFFFAOYSA-N 0.000 description 1
- KLZHVQLVHUKPDX-UHFFFAOYSA-N C1CNC(=O)CN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 Chemical compound C1CNC(=O)CN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 KLZHVQLVHUKPDX-UHFFFAOYSA-N 0.000 description 1
- YVNULDAZKYQVDS-UHFFFAOYSA-N C1CNC(C)CN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 Chemical compound C1CNC(C)CN1C1=CC=C(NC=C2C(N(C=3C=CC=CC=3)N=C22)=O)C2=N1 YVNULDAZKYQVDS-UHFFFAOYSA-N 0.000 description 1
- FFZGJASKWJYJNW-UHFFFAOYSA-N C1CNC(C)CN1C1=CC=C(NC=C2C(N(C=3N=CC=CC=3)N=C22)=O)C2=N1 Chemical compound C1CNC(C)CN1C1=CC=C(NC=C2C(N(C=3N=CC=CC=3)N=C22)=O)C2=N1 FFZGJASKWJYJNW-UHFFFAOYSA-N 0.000 description 1
- NMHFYWRIOOECQN-UHFFFAOYSA-N CC(C1)NCCN1c(nc1C2=NN3C4=CCCC=C4)ccc1NC=C2C3=O Chemical compound CC(C1)NCCN1c(nc1C2=NN3C4=CCCC=C4)ccc1NC=C2C3=O NMHFYWRIOOECQN-UHFFFAOYSA-N 0.000 description 1
- FOTKYIWMODTMLW-UHFFFAOYSA-N CCOC(C(C(C1CC=N2)Cl)C=NC1=C2Cl)=O Chemical compound CCOC(C(C(C1CC=N2)Cl)C=NC1=C2Cl)=O FOTKYIWMODTMLW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- 229910003251 Na K Inorganic materials 0.000 description 1
- LPZWZHOTMKOSHR-UHFFFAOYSA-N O=C1C2=CNC=3C(Cl)=NC=CC=3C2=NN1C1=CC=CC=C1 Chemical compound O=C1C2=CNC=3C(Cl)=NC=CC=3C2=NN1C1=CC=CC=C1 LPZWZHOTMKOSHR-UHFFFAOYSA-N 0.000 description 1
- FSNRTTIQMHEDGW-UHFFFAOYSA-N O=C1N(C=2C=CC=CC=2)N=C(C2=CC=N3)C1=CNC2=C3N1CCOCC1 Chemical compound O=C1N(C=2C=CC=CC=2)N=C(C2=CC=N3)C1=CNC2=C3N1CCOCC1 FSNRTTIQMHEDGW-UHFFFAOYSA-N 0.000 description 1
- AOAMOTSYCNVTRA-UHFFFAOYSA-N O=C1N(C=2C=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N(CC1)CCN1C1=CC=CC=C1 Chemical compound O=C1N(C=2C=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N(CC1)CCN1C1=CC=CC=C1 AOAMOTSYCNVTRA-UHFFFAOYSA-N 0.000 description 1
- OCLHBAOJPIDREO-UHFFFAOYSA-N O=C1N(C=2C=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCCC1 Chemical compound O=C1N(C=2C=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCCC1 OCLHBAOJPIDREO-UHFFFAOYSA-N 0.000 description 1
- PVXJJBUJBFOSKI-UHFFFAOYSA-N O=C1N(C=2C=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCCNCC1 Chemical compound O=C1N(C=2C=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCCNCC1 PVXJJBUJBFOSKI-UHFFFAOYSA-N 0.000 description 1
- MIJLICUDIUQQPQ-UHFFFAOYSA-N O=C1N(C=2C=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCOCC1 Chemical compound O=C1N(C=2C=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCOCC1 MIJLICUDIUQQPQ-UHFFFAOYSA-N 0.000 description 1
- FFXIAKPIQXSHEB-UHFFFAOYSA-N O=C1N(C=2N=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCOCC1 Chemical compound O=C1N(C=2N=CC=CC=2)N=C(C2=N3)C1=CNC2=CC=C3N1CCOCC1 FFXIAKPIQXSHEB-UHFFFAOYSA-N 0.000 description 1
- QSRRRWKMFBVGQJ-UHFFFAOYSA-N OCC(CCC1)CN1c(nc1C2=NN3C4=CCCCC4)ccc1NC=C2C3=O Chemical compound OCC(CCC1)CN1c(nc1C2=NN3C4=CCCCC4)ccc1NC=C2C3=O QSRRRWKMFBVGQJ-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- FGEASBKBMNLZQR-UHFFFAOYSA-N [C].[O].[O] Chemical compound [C].[O].[O] FGEASBKBMNLZQR-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000009901 attention process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000036992 cognitive tasks Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000001934 cyclohexanes Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- ZPHRASBBSVSJJF-UHFFFAOYSA-N ethyl 4,7-dichloro-1,6-naphthyridine-3-carboxylate Chemical compound C1=C(Cl)N=CC2=C(Cl)C(C(=O)OCC)=CN=C21 ZPHRASBBSVSJJF-UHFFFAOYSA-N 0.000 description 1
- MKWUPCSLSDLXQC-UHFFFAOYSA-N ethyl 4,8-dichloro-1,7-naphthyridine-3-carboxylate Chemical compound ClC1=NC=CC2=C(Cl)C(C(=O)OCC)=CN=C21 MKWUPCSLSDLXQC-UHFFFAOYSA-N 0.000 description 1
- DBGPGTXEGGUYSF-UHFFFAOYSA-N ethyl 4-chloro-6-fluoro-1,5-naphthyridine-3-carboxylate Chemical compound C1=CC(F)=NC2=C(Cl)C(C(=O)OCC)=CN=C21 DBGPGTXEGGUYSF-UHFFFAOYSA-N 0.000 description 1
- BXVVELXARNOMPY-UHFFFAOYSA-N ethyl 6-fluoro-4-oxo-1h-1,5-naphthyridine-3-carboxylate Chemical compound C1=CC(F)=NC2=C(O)C(C(=O)OCC)=CN=C21 BXVVELXARNOMPY-UHFFFAOYSA-N 0.000 description 1
- DANFNIHHHTWXTP-UHFFFAOYSA-N ethyl 7-chloro-4-oxo-1h-1,6-naphthyridine-3-carboxylate Chemical compound C1=C(Cl)N=CC2=C(O)C(C(=O)OCC)=CN=C21 DANFNIHHHTWXTP-UHFFFAOYSA-N 0.000 description 1
- VDIBEFAECLBGKD-UHFFFAOYSA-N ethyl 8-chloro-4-oxo-1h-1,7-naphthyridine-3-carboxylate Chemical compound ClC1=NC=CC2=C(O)C(C(=O)OCC)=CN=C21 VDIBEFAECLBGKD-UHFFFAOYSA-N 0.000 description 1
- 239000000374 eutectic mixture Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008801 hippocampal function Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 1
- VUNPWIPIOOMCPT-UHFFFAOYSA-N piperidin-3-ylmethanol Chemical compound OCC1CCCNC1 VUNPWIPIOOMCPT-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Chemical class 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94300007P | 2007-06-08 | 2007-06-08 | |
| PCT/US2008/066211 WO2008154447A1 (en) | 2007-06-08 | 2008-06-06 | Therapeutic pyrazolonaphthyridine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010529145A true JP2010529145A (ja) | 2010-08-26 |
| JP2010529145A5 JP2010529145A5 (enExample) | 2011-07-14 |
Family
ID=40130166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511393A Pending JP2010529145A (ja) | 2007-06-08 | 2008-06-06 | 治療用ピラゾロナフチリジン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7858614B2 (enExample) |
| EP (1) | EP2166853B1 (enExample) |
| JP (1) | JP2010529145A (enExample) |
| KR (1) | KR20100036306A (enExample) |
| CN (1) | CN101754681A (enExample) |
| AU (1) | AU2008261803A1 (enExample) |
| BR (1) | BRPI0812369A2 (enExample) |
| CA (1) | CA2689934A1 (enExample) |
| ES (1) | ES2483728T3 (enExample) |
| IL (1) | IL202287A0 (enExample) |
| MX (1) | MX2009013197A (enExample) |
| WO (1) | WO2008154447A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010529144A (ja) * | 2007-06-08 | 2010-08-26 | ヘリコン・セラピューティクス・インコーポレーテッド | 治療用ピラゾロキノリン尿素誘導体 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012470B2 (en) | 2010-10-14 | 2015-04-21 | Dart Neuroscience (Cayman) Ltd. | Therapeutic 5,6,5-tricyclic analogs |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| US10531200B2 (en) * | 2015-10-23 | 2020-01-07 | Harman International Industries, Incorporated | Dual asymmetric compression driver |
| CN106810550A (zh) * | 2017-01-10 | 2017-06-09 | 湖南华腾制药有限公司 | 一种萘啶衍生物的制备方法 |
| US11485733B2 (en) | 2017-06-30 | 2022-11-01 | Bayer Animal Health Gmbh | Azaquinoline derivatives |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59130882A (ja) * | 1983-01-10 | 1984-07-27 | チバ−ガイギ−・アクチエンゲゼルシヤフト | 複素環縮合ピラゾロ〔３，４−ｄ〕ピリジン−３−オン |
| JPH06184145A (ja) * | 1992-08-27 | 1994-07-05 | Elf Sanofi | チエニル−またはピロリル−カルボン酸誘導体、製法および医薬組成物 |
| JPH09506634A (ja) * | 1994-05-24 | 1997-06-30 | エフ・ホフマン−ラ ロシュ アーゲー | 三環式ジカルボニル誘導体 |
| WO2002081474A1 (en) * | 2001-04-04 | 2002-10-17 | Merck Sharp & Dohme Limited | Triazolophthalazine / quinoline / isoquinoline derivatives which are ligands for gaba-a receptors containing the alpha 5 subtype |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3204126A1 (de) * | 1982-02-06 | 1983-08-11 | Bayer Ag, 5090 Leverkusen | Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US4814450A (en) | 1984-07-09 | 1989-03-21 | Ciba-Geigy Corporation | Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives |
| JPS61112075A (ja) * | 1984-11-05 | 1986-05-30 | Shionogi & Co Ltd | チエニルピラゾロキノリン誘導体 |
| EP0214092A1 (en) | 1985-08-08 | 1987-03-11 | Ciba-Geigy Ag | Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone |
| US4817450A (en) * | 1987-11-30 | 1989-04-04 | Spedco, Inc. | Pressure/temperature test plug assembly |
| US5334595A (en) * | 1992-10-23 | 1994-08-02 | Sterling Winthrop Inc. | Pyrazoloquinolones as anticancer agents |
| GB9716344D0 (en) * | 1997-08-01 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic compounds |
| GB9716347D0 (en) * | 1997-08-01 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic compounds |
| GB9716345D0 (en) * | 1997-08-01 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic compounds |
| TWI271406B (en) * | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
| JP3896309B2 (ja) * | 2001-07-09 | 2007-03-22 | ファイザー株式会社 | プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体 |
| ATE425164T1 (de) * | 2002-12-16 | 2009-03-15 | Active Biotech Ab | Tetrazyklische immunmodulierende verbindungen |
| AR045689A1 (es) * | 2003-05-29 | 2005-11-09 | Millennium Pharm Inc | Compuestos derivados de 2,5-dihidro-pirazolo[4,3-c]quinolin-4-ona como inhibidores de chk-1 y composiciones farmaceuticas que los contienen |
| US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| CN1893943A (zh) * | 2003-10-03 | 2007-01-10 | 3M创新有限公司 | 吡唑并吡啶和其类似物 |
| AU2006287378A1 (en) * | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by HDac inhibition |
| ES2386168T3 (es) * | 2007-06-08 | 2012-08-10 | Helicon Therapeutics, Inc. | Derivados de pirazoloquinolina terapéuticos |
-
2008
- 2008-06-06 ES ES08770412.8T patent/ES2483728T3/es active Active
- 2008-06-06 US US12/135,045 patent/US7858614B2/en not_active Expired - Fee Related
- 2008-06-06 JP JP2010511393A patent/JP2010529145A/ja active Pending
- 2008-06-06 CA CA2689934A patent/CA2689934A1/en not_active Abandoned
- 2008-06-06 MX MX2009013197A patent/MX2009013197A/es active IP Right Grant
- 2008-06-06 BR BRPI0812369A patent/BRPI0812369A2/pt not_active IP Right Cessation
- 2008-06-06 KR KR1020107000331A patent/KR20100036306A/ko not_active Withdrawn
- 2008-06-06 AU AU2008261803A patent/AU2008261803A1/en not_active Abandoned
- 2008-06-06 CN CN200880025152A patent/CN101754681A/zh active Pending
- 2008-06-06 EP EP08770412.8A patent/EP2166853B1/en not_active Not-in-force
- 2008-06-06 WO PCT/US2008/066211 patent/WO2008154447A1/en not_active Ceased
-
2009
- 2009-11-23 IL IL202287A patent/IL202287A0/en unknown
-
2010
- 2010-11-18 US US12/949,619 patent/US8497262B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59130882A (ja) * | 1983-01-10 | 1984-07-27 | チバ−ガイギ−・アクチエンゲゼルシヤフト | 複素環縮合ピラゾロ〔３，４−ｄ〕ピリジン−３−オン |
| JPH06184145A (ja) * | 1992-08-27 | 1994-07-05 | Elf Sanofi | チエニル−またはピロリル−カルボン酸誘導体、製法および医薬組成物 |
| JPH09506634A (ja) * | 1994-05-24 | 1997-06-30 | エフ・ホフマン−ラ ロシュ アーゲー | 三環式ジカルボニル誘導体 |
| WO2002081474A1 (en) * | 2001-04-04 | 2002-10-17 | Merck Sharp & Dohme Limited | Triazolophthalazine / quinoline / isoquinoline derivatives which are ligands for gaba-a receptors containing the alpha 5 subtype |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010529144A (ja) * | 2007-06-08 | 2010-08-26 | ヘリコン・セラピューティクス・インコーポレーテッド | 治療用ピラゾロキノリン尿素誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1142774A1 (en) | 2010-12-17 |
| EP2166853B1 (en) | 2014-05-28 |
| EP2166853A4 (en) | 2011-04-06 |
| CN101754681A (zh) | 2010-06-23 |
| MX2009013197A (es) | 2010-04-27 |
| KR20100036306A (ko) | 2010-04-07 |
| US20110065692A1 (en) | 2011-03-17 |
| AU2008261803A1 (en) | 2008-12-18 |
| WO2008154447A1 (en) | 2008-12-18 |
| EP2166853A1 (en) | 2010-03-31 |
| BRPI0812369A2 (pt) | 2016-08-09 |
| US8497262B2 (en) | 2013-07-30 |
| ES2483728T3 (es) | 2014-08-07 |
| IL202287A0 (en) | 2010-06-16 |
| US20090005365A1 (en) | 2009-01-01 |
| US7858614B2 (en) | 2010-12-28 |
| CA2689934A1 (en) | 2008-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8343957B2 (en) | Therapeutic pyrazoloquinoline urea derivatives | |
| US8497262B2 (en) | Therapeutic pyrazolonaphthyridine derivatives | |
| JP2010529145A5 (enExample) | ||
| US8598159B2 (en) | Therapeutic pyrazoloquinoline derivatives | |
| HK1144892A (en) | Therapeutic pyrazolonaphthyridine derivatives | |
| HK1142774B (en) | Therapeutic pyrazolonaphthyridine derivatives | |
| US9012470B2 (en) | Therapeutic 5,6,5-tricyclic analogs | |
| HK1144891A (zh) | 治疗用吡唑并喹啉衍生物 | |
| HK1142776A (en) | Therapeutic pyrazoloquinoline urea derivatives | |
| HK1142775B (en) | Therapeutic pyrazoloquinoline derivatives | |
| HK1142496B (en) | Therapeutic pyrazoloquinoline urea derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100716 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110525 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110525 Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110525 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130613 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130618 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131210 |